泛昔洛韦分别联合干扰素γ、胸腺肽抗乙肝病毒疗效的临床观察

Objective To observe the efficacy of anti - HBV DNA medicine and different combina-tion. Methods 170 ASC CHB patients were categorized into two groups(group Ⅰ,havs 65 patients,theywere randomised to receive Famcilovir combine with Interferon- γ;group Ⅱ ,havs 105 patients they wererandomised to receive Famcilovir combine with Thymopentin), the controls treat by Interferon - a2b. Re-sult 53.3% of the group Ⅰ and 38.3% of the group Ⅱ had undetectable serum HBV DNA,comparedwith 28.6% in the control group:the people diminition 102 coples/ml,38.8% of whom are in the groupⅠ ,49.5% whom are in the group Ⅱ ,compared with 28.6% in control group(P ＜ 0.025);After treat-ment, they also go down more obviously in HBeAg HbsAg and the group Ⅰ is better than the group Ⅱ.Conclusion Conbination of two different medicine is a useful method, and it may indicate that muchtime is neccssary to receive anti - HBV DNA patients, especially to theose accept immune trcatment.